Oncotelic (OTLC) Director/CMO Anthony Maida Receives RSU Award

What Happened
Anthony E. Maida III, a Director and the CMO – Translational Medicine at Oncotelic Therapeutics (OTLC), was granted 1,500 restricted stock units (RSUs) on July 10, 2026. The RSUs were reported as an award (transaction code A) at $0.00 (no immediate cash purchase). Each RSU will, on vesting, be settled for one share of the issuer’s Series A Convertible Preferred Stock; each preferred share is convertible into 1,000 shares of the company’s common stock — meaning the grant represents a contingent potential of up to 1,500,000 common shares if all RSUs ultimately vest and convert. This is a compensation award rather than an open‑market purchase or sale.

Key Details

• Transaction date: July 10, 2026; Form 4 filed July 14, 2026 (within the two business‑day filing window).
• Grant: 1,500 RSUs; reported acquisition price $0.00; derivative instrument (RSU → Series A preferred → convertible to common).
• Shares owned after transaction: Not specified in the filing.
• Footnote highlights:
  • F1: Each RSU settles into one share of Series A Convertible Preferred, each convertible into 1,000 common shares.
  • F2: Vesting requires an uplisting of the common stock to a national securities exchange on or before June 30, 2027 (or later if the Board approves), plus the reporting person’s continued service for six months after the uplisting.
• Filing timeliness: Report filed within the standard two business days after the transaction date.

Context
This is a time- and performance‑conditioned equity award (compensation), not a market purchase or sale. The RSUs carry no guaranteed immediate economic value for shareholders until the vesting condition (notably an uplisting) is met and the RSUs are settled and converted; therefore the potential common‑share impact is contingent and may not occur. Awards like this are common for executives and directors as compensation/incentive and do not by themselves indicate trading sentiment.